Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Conditions

• Malignant Neoplasm of Stomach Stage II

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Apatinib — DRUG
  Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
• Paclitaxel-based chemotherapeutic regimens — DRUG
  Paclitaxel-based chemotherapeutic regimens including: 1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. 2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. 3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days 4. other paclitaxel-based regimens

Study Details

A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.

Key Dates

Start date

Aug 1, 2016

Status verified

Oct 2018

Primary completion

Mar 31, 2018

Completion

Oct 31, 2018

Study Design

Enrollment

20 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Experimental: Apatinib plus chemotherapy

Primary Outcome Measure

disease control rate(DCR) [ Time Frame: 6 months ]